Mouse Study Maps Brain Circuit That Turns Placebo Expectation Into Painkilling Chemistry

Reverse-translating a validated human placebo protocol into mice, a UC San Diego-led team reports that endogenous opioid release in a single midbrain region, the ventrolateral periaqueductal gray, is required for placebo pain relief to occur, a mechanistic step beyond decades of human brain-imaging correlations.

A multi-institutional team led by Matthew Banghart at the University of California San Diego has identified a brain circuit that is causally necessary for placebo pain relief in mice, moving the phenomenon from correlation to mechanism for the first time in an animal model built directly on a human protocol. Published online April 16, 2026 in Neuron, the study conditioned mice to associate a context with morphine paired with a painful stimulus, then tested them with an inert substance in that same context, mirroring conditioning paradigms used in human placebo research. Mice that showed a placebo response experienced roughly 40 to 60 percent of the pain relief seen with actual morphine, depending on the protocol, and the effect vanished entirely when the researchers gave naloxone, a drug that blocks opioid receptors, indicating the relief depended on opioids the animals' own brains released rather than any external drug.

Human neuroimaging studies going back years have linked placebo analgesia to activity in the prefrontal cortex, anterior cingulate cortex and periaqueductal gray, and to opioid-receptor blockade experiments showing naloxone can dampen placebo effects in people. What those studies could not do was manipulate the circuit directly to test necessity. The new work did that in mice: descending neurons in the ventrolateral periaqueductal gray (vlPAG) that project to the brainstem's rostroventromedial medulla proved essential for both morphine-induced and placebo-induced pain relief, but inputs from the medial prefrontal and anterior cingulate cortices to the vlPAG were required only for the placebo effect, not for morphine's direct action. Conditioning also increased opioid release in the vlPAG each time the mice encountered a painful stimulus after training, and the placebo effect generalized beyond the pain type used in training to other pain measures, including apparent affective distress behaviors, and even to pain from an injury administered after the placebo protocol had ended.

The researchers describe the work as the first to establish placebo mechanisms by directly adapting a protocol validated in human placebo research for use in mice, intended to let future circuit-level experiments in mice inform questions about human placebo pain relief rather than the reverse. Whether the specific circuit and opioid dependence they mapped operates the same way in the human brain has not been tested here and would require separate confirmation in people.

The authors frame the finding as a starting point for asking whether deliberately built expectation, delivered safely and ethically, could one day supplement pain treatment, but they stop short of proposing any clinical use, and no human trial of the circuit-targeted approach has been reported.